参考文献 References
[1] Elster N, Collins D M, Toomey S, et al. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer[J]. Breast Cancer Research and Treatment, 2015, 149(1):5-15.
[2] Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, et al. Biological therapies in nonsmall cell lung cancer[J]. European Respiratory Journal, 2017, 49(3):1601520.
[3] Yu A F, Yadav N U, Lung B Y, et al. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer[J]. Breast Cancer Research and Treatment,2015,149(2):489-495.
[4] David J, William P, Gregory J R, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.[J]. Journal of Clinical Oncology, 2010, 28(2):357-360.
[5] Tinoco G, Warsch S, Glück S, et al. Treating Breast Cancer in the 21st Century: Emerging Biological Therapies[J]. Journal of Cancer,2013,4(2):117-132.
[6] Gagliato D D M, Jardim D L F, Marchesi M S P, et al. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer[J]. Oncotarget, 2016, 7(39).
[7] Hilda W, Roland L, Ava K, et al. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer.[J]. The oncologist,2011,16(11).
[8] Scaltriti M, Rojo F, Ocaa A, et al. Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer[J]. Journal of the National Cancer Institute, 2007, 99(8):628-638.
[9] Mitra D, Brumlik M J, Okamgba S U,et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance[J]. Molecular Cancer Therapeutics, 2009, 8(8):2152.
[10] Zardavas D, Phillips W A, Loi S. PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data[J]. Breast cancer research : BCR,2014,16(1):201.
[11] Cizkova M, Susini A, Vacher S, et al. PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups[J]. Breast Cancer Res,2012,14(1):R28.
[12] Davis N M, Sokolosky M, Stadelman K, et al. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention[J]. Oncotarget,2014,5(13):4603-4650.
[13] Mei‐Ling Chong, Loh M, Thakkar B, et al. Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation[J]. International Journal of Cancer, 2013, 134(5):1232-1238.
[14] Esteva F J, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K Status[J]. The American Journal of Pathology,2010,177(4):1647-1656.
[15] Esteva F J. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment[J]. Breast diseases,2014,25(3).
[16] Anastasi S, Sala G, Huiping C, et al. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin[J]. Oncogene, 24(28):4540-8.
[17] Yarden Y, Pines G. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology [J]. Nature Reviews Cancer, 2012, 12(8):553-563.
[18] Gallardo A, Lerma E, Escuin D, et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas[J]. British Journal of Cancer, 2012, 106(8):1367-1373.
[19] José B, Ian B, Holger E, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.[J]. Lancet (London, England),2012,379(9816).
[20] Untch M P, Loibl S M, Bischoff J M, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial[J]. The lancet oncology,2012,13(2):135-144.
[21] Ritwik G, Archana N, Shizhen Emily W, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.[J]. Cancer research,2011,71(5).
[22] Shizhen Emily W, Bin X, Marta G, et al. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.[J]. Molecular and cellular biology,2008,28(18).
[23] Dianbo Y, Chaoliu D, Songlin P. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation.[J]. Molecular cancer research : MCR,2011,9(12).
[24] Wu Y, Ginther C, Kim J , et al. Expression of Wnt3 Activates Wnt/β-Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells[J]. Molecular Cancer Research, 2012, 10(12):1597-1606.
[25] 叶星明，王淋，贾静，等. miR-375靶向YAP1调控上皮-间质转化参与乳腺癌细胞曲妥珠单抗的耐药[J]. 中国癌症杂志,2021,31(1)：8.
[26] John M L, Patrick S, Hui L, et al. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain.[J]. Proceedings of the National Academy of Sciences of the United States of America,2012,109(37).
[27] Clynes R A, Towers T L, Presta L G, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.[J]. Nature Medicine, 2000, 6(4):443-446.
[28] Michaud H, Eliaou J, Lafont V, et al. Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity[J]. Oncoimmunology.,2014,3(9).
[29] Zhu E, Gai S, Opel C, et al. Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2[J]. Cancer Cell, 2015, 27(4):489-501.
[30] Chao M P, Alizadeh A A, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.[J]. Cell, 2010, 142(5):699-713.
[31] Perruche S, Zhang P, Liu Y, et al. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells.[J]. Nature medicine, 2008, 14(5):528-535.
[32] Su S, Zhao, Y Xing, et al. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages[J]. Cell, 2018, 175(2):442-457.e23.
[33] Janjigian Y Y, Maron S B, Chatila W K , et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial[J]. The Lancet Oncology, 2020, 21(6).
[34] Samantha E G, Katherine J W, Jayashree P J, et al. Mechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines.[J]. Current pharmacogenomics and personalized medicine,2013,11(1).
[35] Joshi J P, Brown N E, Griner S E, et al. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells[J]. Biochemical Pharmacology,2011,82(9):1090-1099.